Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UNITED THERAPEUTICS CORPORATION

(UTHR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
184.32(c) 186.36(c) 192.27(c) 190.66(c) 191.01(c) Last
632 485 279 657 437 619 226 842 197 940 Volume
-1.47% +1.11% +3.17% -0.84% +0.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 672 M - -
Net income 2021 524 M - -
Net cash position 2021 509 M - -
P/E ratio 2021 16,8x
Yield 2021 -
Sales 2022 1 868 M - -
Net income 2022 734 M - -
Net cash position 2022 1 153 M - -
P/E ratio 2022 11,7x
Yield 2022 -
Capitalization 8 575 M 8 575 M -
EV / Sales 2021 4,82x
EV / Sales 2022 3,97x
Nbr of Employees 950
Free-Float 60,7%
More Financials
Company
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil)... 
More about the company
Ratings of United Therapeutics Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about UNITED THERAPEUTICS CORPORATION
10/21INSIDER SELL : United Therapeutics
MT
10/21United Therapeutics Corporation Details New Data Presented at Chest Annual Meeting 2021
CI
10/18MannKind Corporation and United Therapeutics Corporation Enter into an Amendment to the..
CI
10/18Today on Wall Street: This is the real test
10/18UNITED THERAPEUTICS : U.S. FDA declines to approve United-MannKind's lung disease therapy
RE
10/18UNITED THERAPEUTICS : Says FDA Letter Cites Single Deficiency in Hypertension Drug Tyvaso ..
MT
10/18UNITED THERAPEUTICS : Provides an Update on the Progress of the Tyvaso DPI™ New Drug..
PU
10/18UNITED THERAPEUTICS : U.S. FDA declines to approve United Therapeutics' lung disease drug
RE
10/18UNITED THERAPEUTICS CORP : Other Events (form 8-K)
AQ
10/18UNITED THERAPEUTICS : Provides an Update on the Progress of the Tyvaso DPI™ New Drug..
PR
10/18United Therapeutics Corporation Provides an Update on the Progress of the Tyvaso DPI™ N..
CI
10/18United Therapeutics New Drug Application Declined Pending Inspection Issue
DJ
10/11LIQUIDIA : Receives Favorable Ruling in Inter Partes Review against United Therapeutics Pa..
AQ
10/11United Therapeutics to Present New Data At Chest Annual Meeting 2021
CI
10/11LIQUIDIA : Gets Favorable US Patent Panel Ruling in Inter Partes Review Against United The..
MT
More news
News in other languages on UNITED THERAPEUTICS CORPORATION
10/21VENTE D'INITIÉS : United Therapeutics
10/18MÄRKTE USA/Börse hakt schwache Daten ab - Technologiewerte gesucht
10/18MÄRKTE USA/Erholt von Anfangsverlusten - Technologiewerte vorne
10/11Liquidia obtient une décision favorable du panel des brevets américains dans le cadre d..
09/15CAE et BETA Technologies détaillent leur partenariat stratégique pour le programme de f..
More news
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
More recommendations
Stock Trading Strategies
UNITED THERAPEUTICS CORPORATION - 2020
The technical configuration is positive
BUY
More Stock Trading Analysis
Chart UNITED THERAPEUTICS CORPORATION
Duration : Period :
United Therapeutics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 191,01 $
Average target price 231,89 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Martine A. Rothblatt Chairman & Chief Executive Officer
Michael Ian Benkowitz President & Chief Operating Officer
James Christopher Edgemond Chief Financial Officer & Treasurer
Raymond C. Kurzweil Independent Director
Louis Wade Sullivan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNITED THERAPEUTICS CORPORATION25.84%8 575
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455